References
- Bates GJ, Fox SB, Han C, et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol Off J Am Soc Clin Oncol, 24(34), 5373–5380.
- Bettelli E, Dastrange M, Oukka M. (2005). Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA, 102(14), 5138–5143.
- Brunkow ME, Jeffery EW, Hjerrild KA, et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 27(1), 68–73.
- Casetti R, Agrati C, Wallace M, et al. (2009). Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol (Baltimore, MD, 1950), 183(6), 3574–3577.
- Chevalier MF, Weiss L. (2013). The split personality of regulatory T cells in HIV infection. Blood, 121(1), 29–37.
- Coffelt SB, Kersten K, Doornebal CW, et al. (2015). IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 522(7556), 345–348.
- Curiel TJ, Coukos G, Zou L, et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10(9), 942–949.
- Deryugina EI, Zajac E, Juncker-Jensen A, et al. (2014). Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia (New York, NY), 16(10), 771–788.
- Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. (2014). Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest, 124(12), 5466–5480.
- Fontenot JD, Gavin MA, Rudensky AY. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 4(4), 330–336.
- Fridlender ZG, Albelda SM. (2012). Tumor-associated neutrophils: Friend or foe? Carcinogenesis, 33(5), 949–955.
- Gao Q, Qiu SJ, Fan J, et al. (2007). Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol Off J Am Soc Clin Oncol, 25(18), 2586–2593.
- Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB. (1991). Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: Potential model for thymic education. Proc Natl Acad Sci USA, 88(13), 5528–5532.
- Godfrey VL, Wilkinson JE, Russell LB. (1991). X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol, 138(6), 1379–1387.
- Griffiths RW, Elkord E, Gilham DE, et al. (2007). Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother CII, 56(11), 1743–1753.
- Harly C, Guillaume Y, Nedellec S, et al. (2012). Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood, 120(11), 2269–2279.
- Hearps AC, Martin GE, Rajasuriar R, Crowe SM. (2014). Inflammatory co-morbidities in HIV+ individuals: Learning lessons from healthy ageing. Curr HIV/AIDS Rep, 11(1), 20–34.
- Hiraoka N, Onozato K, Kosuge T, Hirohashi S. (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res Off J Am Assoc Cancer Res, 12(18), 5423–5434.
- Hori S, Nomura T, Sakaguchi S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Sci (New York, NY), 299(5609), 1057–1061.
- Hua F, Kang N, Gao YA, et al. (2013). Potential regulatory role of in vitro-expanded Vdelta1 T cells from human peripheral blood. Immunol Res, 56(1), 172–180.
- Huang B, Pan PY, Li Q, et al. (2006). Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res, 66(2), 1123–1131.
- Iida N, Dzutsev A, Stewart CA, et al. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Sci (New York, NY), 342(6161), 967–970.
- Kang N, Tang L, Li X, et al. (2009). Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol Lett, 125(2), 105–113.
- Khaitan A, Kravietz A, Mwamzuka M, et al. (2016). FOXP3+Helios+ regulatory T cells, immune activation and advancing disease in HIV infected children. J Acquir Immune Defic Syndr, 72(5), 474–484.
- Kuhl AA, Pawlowski NN, Grollich K, et al. (2009). Human peripheral gammadelta T cells possess regulatory potential. Immunology, 128(4), 580–588.
- Ladoire S, Martin F, Ghiringhelli F. (2011). Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol Immunother CII, 60(7), 909–918.
- Lai C, August S, Albibas A, et al. (2016). OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T cell responses and associate with metastatic potential. Clin Cancer Res Off [Epub ahead of print].
- Legut M, Cole DK, Sewell AK. (2015). The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy. Cell Mol Immunol, 12(6), 656–668.
- Li B, Samanta A, Song X, et al. (2007). FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA, 104(11), 4571–4576.
- Manjili MH. (2012). Phenotypic plasticity of MDSC in cancers. Immunol Invest, 41(6–7), 711–721.
- Marvel D, Gabrilovich DI. (2015). Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest, 125(9), 3356–3364.
- Mercer F, Khaitan A, Kozhaya L, et al. (2014). Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. J Immunol (Baltimore, Md.: 1950), 193(3), 1047–1054.
- Mishalian I, Bayuh R, Eruslanov E, et al. (2014). Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17–a new mechanism of impaired antitumor immunity. Int J Cancer, 135(5), 1178–1186.
- Miyara M, Yoshioka Y, Kitoh A, et al. (2009). Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6), 899–911.
- Mougiakakos D, Choudhury A, Lladser A, et al. (2010). Regulatory T cells in cancer. Adv Cancer Res, 107, 57–117.
- Ono M, Yaguchi H, Ohkura N, et al. (2007). Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature, 446(7136), 685–689.
- Pan PY, Ma G, Weber KJ, et al. (2010). Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res, 70(1), 99–108.
- Patel SS, Wacholtz MC, Duby AD, et al. (1989). Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. J Immunol (Baltimore, MD, 1950), 143(4), 1108–1117.
- Perrone G, Ruffini PA, Catalano V, et al. (2008). Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (Oxford, England: 1990), 44(13), 1875–1882.
- Peters C, Oberg HH, Kabelitz D, Wesch D. (2014). Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells. Cell Mol Life Sci CMLS, 71(10), 1943–1960.
- Petersen RP, Campa MJ, Sperlazza J, et al. 2006. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, 107(12), 2866–2872.
- Rabinovich GA, Conejo-Garcia JR. (2016). Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J Mol Biol [Epub ahead of print]. doi:10.1016/j.jmb.2016.03.021
- Ren JP, Ying RS, Cheng YQ, et al. (2016). HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepatitis [ePub ahead of print]. doi:10.1111/jvh.12537
- Rezende RM, da Cunha AP, Kuhn C, et al. (2015). Identification and characterization of latency-associated peptide-expressing gammadelta T cells. Nat Commun, 6, 8726.
- Rutkowski MR, Stephen TL, Svoronos N, et al. (2015). Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer cell, 27(1), 27–40.
- Salama P, Phillips M, Grieu F, et al. (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol, 27(2), 186–192.
- Schipmann S, Wermker K, Schulze HJ, et al. (2014). Cutaneous and oral squamous cell carcinoma-dual immunosuppression via recruitment of FOXP3+ regulatory T cells and endogenous tumour FOXP3 expression? J Cranio-Maxillo-Facial Surgery Off Publ Eur Assoc Cranio-Maxillo-Facial Surgery, 42(8), 1827–1833.
- Schlecker E, Stojanovic A, Eisen C, et al. (2012). Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (Baltimore, Md.: 1950), 189(12), 5602–5611.
- Serafini P, Mgebroff S, Noonan K, Borrello I. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res, 68(13), 5439–5449.
- Sumpter TL, Payne KK, Wilkes DS. (2008). Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells. J Leukocyte Biol, 83(3), 708–717.
- Toia F, Buccheri S, Anfosso A, et al. (2016). Skewed differentiation of circulating Vgamma9Vdelta2 T lymphocytes in melanoma and impact on clinical outcome. PloS One, 11(2), e0149570.
- Uribe-Querol E, Rosales C. (2015). Neutrophils in cancer: Two sides of the same coin. J Immunol Res, 2015, 983698.
- Vaeth M, Schliesser U, Muller G, et al. (2012). Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci USA, 109(40), 16258–16263.
- Vavassori S, Kumar A, Wan GS, et al. (2013). Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol, 14(9), 908–916.
- Viaud S, Saccheri F, Mignot G, et al. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Sci (New York, NY), 342(6161), 971–976.
- Vignali D. (2008). How many mechanisms do regulatory T cells need? Eur J Immunol, 38(4), 908–911.
- von Lilienfeld-Toal M, Nattermann J, Feldmann G, et al. (2006). Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol, 144(3), 528–533.
- Wang J, Ioan-Facsinay A, van der Voort EI, et al. (2007). Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol, 37(1), 129–138.
- Wu D, Wu P, Wu X, et al. (2015). Expanded human circulating Vdelta1 gammadeltaT cells exhibit favorable therapeutic potential for colon cancer. Oncoimmunology, 4(3), e992749.
- Ye J, Ma C, Wang F, et al. (2013). Specific recruitment of gammadelta regulatory T cells in human breast cancer. Cancer Res, 73(20), 6137–6148.
- Zhou SL, Zhou ZJ, Hu ZQ,et al. (2016). Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology, 150(7), 1646–1658.